Energenesis Biomedical Co., Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (2012)

Organization Overview

First Clinical Trial
2016
NCT02672436
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Energenesis Biomedical Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

energi-f703 (3 trials)

Drugs in Phase 2 Trials (2)

energi-f701 (1 trial)

minoxidil (loniten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Leg Ulcer (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3